Market Intelligence, Clinical Progress, and High-Purity Reagents for Spinal Muscular Atrophy (SMA) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SMN-Exon7/SMN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Native) | SMN1 Full-Length Recombinant Protein (Exon 7 Included) HEK293 Expressed, Native Glycosylation, Sequence Verified, >95% Purity, Endotoxin <1EU/ug |
View SMN1 Products |
| Antigen (Mutant) | SMNΔ7 Protein (Exon 7 Deletion Mutant) For stability comparison assays, Endotoxin Controlled |
View SMN1 Products |
| Gene Delivery | SMN1-ORF Lentivirus Particles Full-length ORF for stable motor neuron cell line construction and AAV vector benchmarking |
View SMN1 Products |
| Splice Target | SMN2 Full-Length Protein & Minigene Systems For ASO splice-switching validation (promotes Exon 7 inclusion) |
View SMN2 Products |
| Benchmark Antibody | Anti-SMN1 (Clone 2B1 Epitope) Sequence Verified Positive Control for Western/ELISA |
View SMN1 Products |
| Validator | SMN1 siRNA Set (3 Unique Sequences) For knockdown specificity verification in splicing assays |
View SMN1 Products |
| Related Target | SMN2 (Survival Motor Neuron 2) Paralog target for splicing modulation therapies |
View SMN2 Products |
| Related Target | IGF1 (Insulin-like Growth Factor 1) Neuroprotective pathway synergistic with SMN upregulation |
View IGF1 Products |
| Related Target | AAV9 Primary viral vector for SMN1 gene replacement therapy |
View AAV9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Exon 7 Inclusion Quantification | Matched Pair: SMN1 (FL) vs SMNΔ7 Mutant Protein Standards, Mass Spec Verified |
| Splice Switching Validation | SMN2 Minigene Reporter Cell Lines with Stable Lentiviral Integration |
| AAV Gene Therapy Titer | SMN1-ORF Specific qPCR Standards with Accurate Copy Number Calibration |
| Off-Target ASO Effects | Negative Control Proteins (SMN Pseudogenes) for Specificity Panels |
| SMN Complex Assembly Validation | GEMIN2 co-incubation-ready proteins; strictly sequence-verified by mass spec |
Live SMN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active SMA Clinical Trials
- ➤ Latest Splice-Switching Research
- ➤ Recent Exon Inclusion Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for SMN1-deficient Spinal Muscular Atrophy has shifted from palliative care to disease modification, following the approval of three mechanistically distinct platforms: antisense oligonucleotide-mediated splicing (Biogen's Nusinersen), viral gene replacement (Novartis' Zolgensma), and small-molecule splicing modifiers (Roche's Risdiplam). Current R&D focuses on next-generation modalities targeting CNS penetration limitations, redosing capabilities for AAV vectors, and combination strategies with neuroprotective agents. The critical unmet need remains in developing assays that can distinguish between SMN1-derived and SMN2-derived protein levels in mixed cell populations, driving demand for sequence-specific detection reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO Splice-Switching | Biogen, Ionis | SMA Type I-IV | Exon 7 Inclusion Reporter Assays (Need SMN2 Minigene Lentivirus) |
| AAV9 Gene Therapy | Novartis, Astellas | Pediatric SMA | SMN1 Expression Standards (Need Full-Length Protein for ELISA Calibration) |
| Small Molecule Splicing | Roche, PTC Therapeutics | Adult SMA | High-Throughput Stability Screens (Need SMNΔ7 Mutant as Negative Control) |
| SMN Stabilizers | Novartis, Scholar Rock | Combination Therapy | Oligomerization Assays (Need Native Folding SMN1 Protein) |
Molecular Differentiation & Assay Strategy
Core Molecular Challenge: SMN1 and SMN2 differ by only 5 nucleotides (C6T in Exon 7, C2722T in Exon 8), leading to distinct splicing outcomes. Drug development must address:
- Splicing Specificity: ASOs must distinguish SMN1 from SMN2 and avoid off-target splicing effects. Assay strategy: dual-fluorescence reporter minigene systems (Exon 7 inclusion = GFP, skipping = RFP), using TarMart's SMN2 lentivirus for stable cell lines.
- Protein Stability Assessment: SMNΔ7 (Exon 7 deletion) protein has a very short half-life; full-length SMN1 forms stable multimers. Assay strategy: cycloheximide chase assay with Western blot, using sequence-verified SMN1 FL vs SMNΔ7 mutant protein standards (TarMart provides >95% purity paired standards).
- CNS Penetration Verification: Small molecule splicing modifiers must cross the blood-brain barrier; ASOs require intrathecal administration. Assay strategy: iPSC-derived motor neuron models, with TarMart's SMN1-Lentivirus transduced reporter lines for compound screening.
- Immunogenicity Control: AAV vectors trigger humoral immunity; ASOs may activate TLRs. Assay strategy: PBMC stimulation assays require high-purity proteins with Endotoxin <1EU/ug as negative controls (TarMart strictly controls endotoxin levels).